English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity

MPS-Authors
/persons/resource/persons182098

Brauns,  Olaf
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182099

Brauns,  Simone
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182219

Jenke,  Marc
Molecular biology of neuronal signals, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182499

Zimmermann,  Bodo
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Brauns, O., Brauns, S., Jenke, M., Zimmermann, B., & Dautzenberg, F. M. (2002). Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity. Peptides, 23(10), 1817-1827.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0029-1917-6
Abstract
Antisauvagine-30 (aSVG) is the only high-affinity antagonist for the corticotropin-releasing factor (CRF) type 2 (CRF2) receptor. A structure-activity relationship study was performed to pinpoint residues conferring aSVG's selectivity. The aSVG- analogues being N-terminally extended by one or two residues or containing the Ala(22)Arg(23)Ala(24) (ARA-motif) of CRF, were synthesized. Additionally, a lactam bridge between positions 29 and 32 was introduced. The modified peptides were analyzed for alpha-helicity properties, binding affinities and antagonistic potencies at the rat CRF1 and mouse CRF2B receptors. While N- terminal prolongation and replacement Of D-Phe(11) by Tyr(11) increased the affinity for the CRF2 receptor, the introduction of the ARA motif resulted in a loss of CRF2 receptor selectivity. These data show that aSVG(10-40) analogues are more potent CRF2 receptor antagonists than aSVG(11-40) peptides, while introduction of the ARA-motif or a cyclic constraint between residues 29 and 32 favors binding to the CRF1 receptor. (C) 2002 Elsevier Science Inc. All rights reserved.